ATE269865T1 - Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren - Google Patents

Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren

Info

Publication number
ATE269865T1
ATE269865T1 AT95932446T AT95932446T ATE269865T1 AT E269865 T1 ATE269865 T1 AT E269865T1 AT 95932446 T AT95932446 T AT 95932446T AT 95932446 T AT95932446 T AT 95932446T AT E269865 T1 ATE269865 T1 AT E269865T1
Authority
AT
Austria
Prior art keywords
pyrazolo
tyrosine kinase
protein tyrosine
quinoxaline
pdgf receptor
Prior art date
Application number
AT95932446T
Other languages
English (en)
Inventor
Michael R Myers
Paul E Persons
Cuong Q Ly
Alfred P Spada
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE269865T1 publication Critical patent/ATE269865T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95932446T 1994-09-08 1995-09-06 Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren ATE269865T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/303,097 US5476851A (en) 1994-09-08 1994-09-08 Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase
PCT/US1995/011414 WO1996007658A1 (en) 1994-09-08 1995-09-06 PYRAZOLO[3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE

Publications (1)

Publication Number Publication Date
ATE269865T1 true ATE269865T1 (de) 2004-07-15

Family

ID=23170524

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95932446T ATE269865T1 (de) 1994-09-08 1995-09-06 Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren

Country Status (10)

Country Link
US (1) US5476851A (de)
EP (1) EP0779889B1 (de)
JP (1) JP3952313B2 (de)
AT (1) ATE269865T1 (de)
AU (1) AU697518B2 (de)
CA (1) CA2198005C (de)
DE (1) DE69533194T2 (de)
ES (1) ES2224134T3 (de)
MX (1) MX9701820A (de)
WO (1) WO1996007658A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007701A1 (en) 1997-08-05 1999-02-18 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
EP1414500A4 (de) * 2001-04-16 2005-01-12 Uab Research Foundation Akt und regulierung der synovialfibroblasten-apoptosis bei ra
AU2003234567A1 (en) * 2002-05-15 2003-12-02 Janssen Pharmaceutica N.V. N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors
US20050130910A1 (en) * 2002-05-15 2005-06-16 Ho Chih Y. Immobilized N-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targets
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
US20090036474A1 (en) * 2004-10-12 2009-02-05 Patrick Ple Quinazoline derivatives for use against cancer
JP2008515960A (ja) * 2004-10-12 2008-05-15 アストラゼネカ アクチボラグ キノリン誘導体
US20060104951A1 (en) * 2004-11-16 2006-05-18 Mountz John D Akt and regulation of RA synovial fibroblast apoptosis
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN112020357B (zh) * 2019-04-02 2023-08-29 上海翰森生物医药科技有限公司 含吲唑基的三并环类衍生物的盐及其晶型
US12616670B2 (en) 2020-03-23 2026-05-05 Helmholtz-Zentrum für Infektionsforschung GmbH N-phenyl-3-mercaptopropanamide derivatives as metallo-beta-lactamase inhibitors for the treatment of bacterial infections
WO2025236095A1 (en) * 2024-05-17 2025-11-20 Congruence Therapeutics Inc. Modulators of alpha-1 antitrypsin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3701277A1 (de) * 1987-01-17 1988-07-28 Boehringer Mannheim Gmbh Neue tricyclische benzimidazole, verfahren zu ihrer herstellung und verwendung als arzneimittel
DK160941C (da) * 1988-06-28 1991-10-21 Novo Nordisk As Kondenserede 2,3-dihydroxypyraziner, fremgangsmaade til deres fremstilling og farmaceutiske praeparater, hvori forbindelserne indgaar
DE69222637T2 (de) * 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
GB9314884D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
EP0779889B1 (de) 2004-06-23
AU697518B2 (en) 1998-10-08
MX9701820A (es) 1997-06-28
EP0779889A1 (de) 1997-06-25
JPH10505093A (ja) 1998-05-19
WO1996007658A1 (en) 1996-03-14
AU3549195A (en) 1996-03-27
ES2224134T3 (es) 2005-03-01
CA2198005C (en) 2007-06-12
JP3952313B2 (ja) 2007-08-01
DE69533194T2 (de) 2005-08-11
CA2198005A1 (en) 1996-03-14
DE69533194D1 (de) 2004-07-29
EP0779889A4 (de) 2000-02-23
US5476851A (en) 1995-12-19

Similar Documents

Publication Publication Date Title
DE69533194D1 (de) PYRAZOLO(3,4-g)CHINOXALINE ALS PDGF-REZEPTOR PROTEIN TYROSIN-KINASE INHIBITOREN
ATE202076T1 (de) Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie
DK0668863T3 (da) Quinuclidinderivat som substans P-antagonist
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BR9917038A (pt) Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias
EA200400283A1 (ru) Производные аминофталазинона, активные как ингибиторы киназ, способ их получения и содержащие их фармацевтические композиции
BR9507073A (pt) Composto processos para preparar o mesmo e para tratar uma doença no sistema nervoso central composiçao farmacêutica e uso do composto
DE60024857D1 (de) Neue verbindungen
DE69824313D1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
PL350891A1 (en) Substituted 1,4-dichlorindene[1,2-c]pyrazoles as inhibitors of tyrosine kinase
DK0823909T3 (da) Hidtil ukendte heterocykliske forbindelser
KR970703152A (ko) 치료제 용도의 피리딜비스인산염(pyridylbisphosphonates for use as a therapeutical agent)
GR3032950T3 (en) Substituted fused and bridged bicyclic compounds as therapeutic agents
CA2301590A1 (en) 2-aminopyridines as inhibitors of cyclooxygenase-2
NZ504124A (en) Phenyl-alkyl-imidazoles and use in treating inflammatory disease
PT1025101E (pt) Derivados de nafto-imidazo¬1,2-a|piridina sua preparacao e uso no tratamento de perturbacoes do sistema nervoso central
RU99118510A (ru) Композиция для лечения или предупреждения рака простаты
LV12459A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
RU94035756A (ru) Производные имидазола, являющиеся ингибиторами питокинов, способы их получения, фармацевтическая композиция

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties